Скачать с ютуб Symposium | Treatment paradigm in early RRMM в хорошем качестве

Symposium | Treatment paradigm in early RRMM

This independent educational activity is supported by GSK. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity. At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium titled: How to sequence BCMA-directed therapies in early relapsed/refractory multiple myeloma (RRMM). During the symposium, Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK, delivered an expert presentation on the existing and developing treatment paradigm for early RRMM. In this presentation, Popat discusses the evolving treatment paradigm for early RRMM, highlighting emerging therapeutic approaches, the expansion of existing therapies into earlier treatment lines, and the latest clinical trial data. Popat emphasizes the importance of tailoring treatments based on patient-specific factors, such as genetic risk, transplant eligibility, and frailty, while considering the place for immunotherapies with different targets in the early relapse setting. Popat discusses promising data associated with the use of BCMA-targeted therapies in earlier lines, as well as the challenges of sequencing these therapies across different patient populations and access issues globally.